Lancet paper finds novel drug regimen could be more effective than existing treatments; TB Alliance’s trial to test drugs in combination saves years in research time.

Recent advances in biomedical HIV, hepatitis C virus, and tuberculosis prevention and treatment are not reaching those who need them most; Political leaders continue to break domestic, global health commitments.

ACTION’s new publication, The Global Fund: Progress at Risk, provides specific examples of where the fight against TB will slow unless donors contribute needed resources.

The We Can End AIDS Mobilization for Economic Justice and Human Rights is on Tuesday, July 24 at 12 noon. TB advocates should join the Sound Policies branch, leaving from the Archives Metro station (see map here: http://www.wecanendaids.org/map.html).

Roadmap of HIV/TB sessions, booths and networking zones.

The Roadmap offers a set of practical and African-owned solutions to enhance sustainable responses to AIDS, TB and malaria. 

The strategy provides a clear definition of CDC's role in global health and will enable the agency to respond effectively to the evolving environment.

The report describes existing TB diagnostics and the pipeline of expected future methods and tools; characterizes unmet needs and the extent to which the pipeline may address these; and highlights areas of persisting market shortcomings.

The growing evidence regarding the burden and detrimental effects of TB among women and children, especially among those living with HIV, highlights the need for improving TB/HIV activities in PMTCT and maternal, newborn, and child health settings.

EMA's response to TB CAB letter regarding conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783).